{"nctId":"NCT00996736","briefTitle":"Mycotic Ulcer Treatment Trial I","startDateStruct":{"date":"2010-04"},"conditions":["Corneal Ulcer","Eye Infections, Fungal"],"count":323,"armGroups":[{"label":"Topical Natamycin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Natamycin"]},{"label":"Topical Voriconazole","type":"EXPERIMENTAL","interventionNames":["Drug: Voriconazole"]}],"interventions":[{"name":"Natamycin","otherNames":[]},{"name":"Voriconazole","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Presence of a corneal ulcer at presentation\n* Evidence of filamentous fungus on smear (KOH wet mount, Giemsa, or Gram stain)\n* Visual acuity between 6/12 (20/40, logMAR 0.3) and 6/120 (20/400, logMAR 1.3)\n* The patient must be able to verbalize a basic understanding of the study after it is explained to the patient, as determined by physician examiner. This understanding must include a commitment to return for follow-up visits.\n* Willingness to be treated as an inpatient or to be treated as an outpatient and return every 3 days +/- 1 day until re-epithelialization and every week to receive fresh medication for 3 weeks\n* Appropriate consent\n\nExclusion Criteria:\n\n* Impending perforation\n* Evidence of bacteria on Gram stain at the time of enrollment\n* Evidence of acanthamoeba by stain\n* Evidence of herpetic keratitis by history or exam\n* Corneal scar not easily distinguishable from current ulcer\n* Age less than 16 years (before 16th birthday)\n* Bilateral ulcers\n* Previous penetrating keratoplasty in the affected eye\n* Pregnancy (by history or urine test) or breast feeding (by history)\n* Acuity worse than 6/60 (2/200) in the fellow eye (note that any acuity, uncorrected, corrected, pinhole, or BSCVA 6/60 or better qualifies for enrollment)\n* Acuity worse than 6/120 (20/400) or better than 6/12 (20/40) in the study eye (note that any acuity, uncorrected, corrected, pinhole, or BSCVA can be used for enrollment)\n* Known allergy to study medications (antifungal or preservative)\n* No light perception in the affected eye\n* Not willing to participate","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Best Spectacle-corrected logMAR Visual Acuity","description":"The primary analysis is best spectacle-corrected logMAR (logarithm of the Minimum Angle or Resolution) visual acuity, correcting for enrollment BSCVA and treatment arm in a multiple linear regression model. The pre-specified non-inferiority margin is less than 1.5 lines logMAR acuity. (Adjusted three-month visual acuity confidence bounds for the difference between the voriconazole and natamycin groups which meet or exceed 0.15 logMAR units would not permit noninferiority to be declared.) Note that this design also allows declaration of superiority (2-sided alpha of 0.05, corrected for an interim analysis).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.39","spread":null},{"groupId":"OG001","value":"0.57","spread":null}]}]}]},{"type":"SECONDARY","title":"Best Spectacle-corrected logMAR Visual Acuity","description":"Best spectacle-corrected logMAR (logarithm of the Minimum Angle of Resolution) visual acuity at 3 weeks after enrollment, adjusting for enrollment BSCVA and treatment arm in a multiple linear regression model","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.49","spread":null},{"groupId":"OG001","value":"0.63","spread":null}]}]}]},{"type":"SECONDARY","title":"Hard Contact Lens-corrected Visual Acuity Measured in logMAR","description":"Hard contact lens-corrected visual acuity measured in logMAR (logarithm of the Minimum Angle of Resolution) 3 months after enrollment","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":null},{"groupId":"OG001","value":"0.30","spread":null}]}]}]},{"type":"SECONDARY","title":"Size of Infiltrate/Scar","description":"Size of infiltrate/scar at 3 weeks and 3 months after enrollment, using enrollment infiltrate scar/size as a covariate","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.30","spread":null},{"groupId":"OG001","value":"3.44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.31","spread":null},{"groupId":"OG001","value":"3.52","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Resolution of Epithelial Defect","description":"Time in days from enrollment to resolution of epithelial defect. For those subjects with more than 21 days to resolution, 21 days was used.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.50","spread":"7.60"},{"groupId":"OG001","value":"11.50","spread":"7.90"}]}]}]},{"type":"SECONDARY","title":"Minimum Inhibitory Concentration of Isolates","description":"Minimum inhibitory concentration (50th percentile) of fungal isolates to natamycin and voriconazole","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Microbiological Cure at 6 Days","description":"Microbiological cure defined as no fungal growth on culture at 6 (+/-1) days from enrollment","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"69","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":42,"n":162},"commonTop":["Increase in infiltrate size > 50%","Increase in hypopyon (>2mm)","Progressive corneal thinning, <=50% of enrollment thickness"]}}}